- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Reforming Oncology Care Payments: Interviews From the QCCA Leadership Summit
As the costs of cancer care continue to rise in the United States, eyes are increasingly turning to payment reform.
As the costs of cancer care continue to rise in the United States, eyes are increasingly turning to payment reform. Research by the Northeast Business Group on Health found that in 2015, employers spent $125 million on cancer care, and since then, cancer therapy costs have increased substantially with greater use of immunotherapy and the introduction of chimeric antigen receptor T-cell therapies that can easily cost half a million dollars for treatment.
The federal government is taking the lead with the Oncology Care Model, which will transition into Oncology Care First in 2022 after a 1-year extension due to the coronavirus disease 2019 pandemic, but commercial payers are also testing payment reform models.
Speakers who participated in the Quality Cancer Care Alliance’s Fall Leadership Summit weighed in on the payment reform space for cancer care.
Listen above or through one of these podcast services:
Read more:
Speaking of Employers: Purchasers Detail the Challenges of Getting a Handle on Oncology Care Costs
Three Ways COVID-19 Makes the Oncology Care First Model More Attractive
Infrastructure of OCM Helps Practices Through COVID-19, Chong Says
A Closer Look at 3 Oncology Payment Reform Projects
Cancer Does Not Stop for COVID-19, but Reform Becomes a Challenge
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Bridging Care Gaps With a Systemwide Value-Based Care Strategy
March 29th 2025Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an integrated system that is able to better provide holistic, value-based care despite the many transitions that continue among hospital, primary, specialty, and community care environments.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
